- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 430791, 9 pages
The Protective Effect of Fasudil on the Structure and Function of Cardiac Mitochondria from Rats with Type 2 Diabetes Induced by Streptozotocin with a High-Fat Diet Is Mediated by the Attenuation of Oxidative Stress
Department of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, 301 Yan Chang Zhong Road, Shanghai 200072, China
Received 19 February 2013; Revised 25 April 2013; Accepted 29 April 2013
Academic Editor: Michael Cunningham
Copyright © 2013 Rong Guo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- H. M. McBride, M. Neuspiel, and S. Wasiak, “Mitochondria: more than just a powerhouse,” Current Biology, vol. 16, no. 14, pp. R551–R560, 2006.
- E. J. Lesnefsky, S. Moghaddas, B. Tandler, J. Kerner, and C. L. Hoppel, “Mitochondrial dysfunction in cardiac disease: ischemia—reperfusion, aging, and heart failure,” Journal of Molecular and Cellular Cardiology, vol. 33, no. 6, pp. 1065–1089, 2001.
- A. M. Walters, G. A. Porter Jr., and P. S. Brookes, “Mitochondria as a drug target in ischemic heart disease and cardiomyopathy,” Circulation Research, vol. 111, no. 9, pp. 1222–1236, 2012.
- G. X. Shen, “Mitochondrial dysfunction, oxidative stress and diabetic cardiovascular disorders,” Cardiovascular & Hematological Disorders—Drug Targets, vol. 12, no. 2, pp. 106–112, 2012.
- G. X. Shen, “Oxidative stress and diabetic cardiovascular disorders: roles of mitochondria and NADPH oxidase,” Canadian Journal of Physiology and Pharmacology, vol. 88, no. 3, pp. 241–248, 2010.
- X. Xie, S. R. Chowdhury, G. Sangle, and G. X. Shen, “Impact of diabetes-associated lipoproteins on oxygen consumption and mitochondrial enzymes in porcine aortic endothelial cells,” Acta Biochimica Polonica, vol. 57, no. 4, pp. 393–398, 2010.
- R. Arita, Y. Hata, S. Nakao et al., “Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage,” Diabetes, vol. 58, no. 1, pp. 215–226, 2009.
- S. J. Guan, Z. H. Ma, Y. L. Wu, et al., “Long-term administration of fasudil improves cardiomyopathy in streptozotocin-induced diabetic rats,” Food and Chemical Toxicology, vol. 50, no. 6, pp. 1874–1882, 2012.
- H. Zhou, Y. J. Li, M. Wang, et al., “Involvement of RhoA/ROCK in myocardial fibrosis in a rat model of type 2 diabetes,” Acta Pharmacologica Sinica, vol. 32, no. 8, pp. 999–1008, 2011.
- I. Kizub, O. Pavlova, C. Johnson, A. Soloviev, and A. Zholos, “Rho kinase and protein kinase C involvement in vascular smooth muscle myofilament calcium sensitization in arteries from diabetic rats,” British Journal of Pharmacology, vol. 159, no. 8, pp. 1724–1731, 2010.
- L. A. Bach, “Rho kinase inhibition: a new approach for treating diabetic nephropathy?” Diabetes, vol. 57, no. 3, pp. 532–533, 2008.
- R. Komers, “Rho kinase inhibition in diabetic nephropathy,” Current Opinion in Nephrology and Hypertension, vol. 20, no. 1, pp. 77–83, 2011.
- T. Ishida, Y. Takanashi, and H. Kiwada, “Safe and efficient drug delivery system with liposomes for intrathecal application of an antivasospastic drug, fasudil,” Biological and Pharmaceutical Bulletin, vol. 29, no. 3, pp. 397–402, 2006.
- I. Omeis, N. A. Jayson, R. Murali, and J. M. Abrahams, “Treatment of cerebral vasospasm with biocompatible controlled-release systems for intracranial drug delivery,” Neurosurgery, vol. 63, no. 6, pp. 1011–1019, 2008.
- M. F. Olson, “Applications for ROCK kinase inhibition,” Current Opinion in Cell Biology, vol. 20, no. 2, pp. 242–248, 2008.
- Y. Suzuki, M. Shibuya, S. I. Satoh, Y. Sugimoto, and K. Takakura, “A postmarketing surveillance study of fasudil treatment after aneurysmal subarachnoid hemorrhage,” Surgical Neurology, vol. 68, no. 2, pp. 126–131, 2007.
- M. J. Reed, K. Meszaros, L. J. Entes et al., “A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat,” Metabolism: Clinical and Experimental, vol. 49, no. 11, pp. 1390–1394, 2000.
- C. P. Baines, C. X. Song, Y. T. Zheng et al., “Protein kinase Cε interacts with and inhibits the permeability transition pore in cardiac mitochondria,” Circulation Research, vol. 92, no. 8, pp. 873–880, 2003.
- S. Javadov, M. Karmazyn, and N. Escobales, “Mitochondrial permeability transition pore opening as a promising therapeutic target in cardiac diseases,” Journal of Pharmacology and Experimental Therapeutics, vol. 330, no. 3, pp. 670–678, 2009.
- Q. Gao, S. Z. Zhang, C. M. Cao, I. C. Bruce, and Q. Xia, “The mitochondrial permeability transition pore and the Ca 2+-activated K + channel contribute to the cardioprotection conferred by tumor necrosis factor-α,” Cytokine, vol. 32, no. 5, pp. 199–205, 2005.
- H. Li, W. Peng, W. Jian, et al., “ROCK inhibitor fasudil attenuated high glucose-induced MCP-1 and VCAM-1 expression and monocyte-endothelial cell adhesion,” Cardiovascular Diabetology, vol. 11, p. 65, 2012.
- L. H. Opie, “Substrate utilization and glycolysis in the heart,” Cardiology, vol. 56, no. 1, pp. 2–21, 1971.
- J. M. Huss and D. P. Kelly, “Mitochondrial energy metabolism in heart failure: a question of balance,” The Journal of Clinical Investigation, vol. 115, no. 3, pp. 547–555, 2005.
- F. Piarulli, G. Sartore, and A. Lapolla, “Glyco-oxidation and cardiovascular complications in type 2 diabetes: a clinical update,” Acta Diabetologica, vol. 50, no. 2, pp. 101–110, 2012.
- D. X. Zhang and D. D. Gutterman, “Mitochondrial reactive oxygen species-mediated signaling in endothelial cells,” American Journal of Physiology, vol. 292, no. 5, pp. H2023–H2031, 2007.
- F. Giacco and M. Brownlee, “Oxidative stress and diabetic complications,” Circulation Research, vol. 107, no. 9, pp. 1058–1070, 2010.
- F. Folli, D. Corradi, P. Fanti, et al., “The role of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro- and macrovascular complications: avenues for a mechanistic-based therapeutic approach,” Current Diabetes Reviews, vol. 7, no. 5, pp. 313–324, 2011.
- B. B. Lowell and G. I. Shulman, “Mitochondrial dysfunction and type 2 diabetes,” Science, vol. 307, no. 5708, pp. 384–387, 2005.
- F. Di Lisa, N. Kaludercic, A. Carpi, R. Menabò, and M. Giorgio, “Mitochondrial pathways for ROS formation and myocardial injury: the relevance of p66Shc and monoamine oxidase,” Basic Research in Cardiology, vol. 104, no. 2, pp. 131–139, 2009.
- F. Di Lisa, N. Kaludercic, A. Carpi, R. Menabò, and M. Giorgio, “Mitochondria and vascular pathology,” Pharmacological Reports, vol. 61, no. 1, pp. 123–130, 2009.
- A. P. Halestrap, S. J. Clarke, and S. A. Javadov, “Mitochondrial permeability transition pore opening during myocardial reperfusion—a target for cardioprotection,” Cardiovascular Research, vol. 61, no. 3, pp. 372–385, 2004.
- J. N. Weiss, P. Korge, H. M. Honda, and P. Ping, “Role of the mitochondrial permeability transition in myocardial disease,” Circulation Research, vol. 93, no. 4, pp. 292–301, 2003.
- M. Higashi, H. Shimokawa, T. Hattori et al., “Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system,” Circulation Research, vol. 93, no. 8, pp. 767–775, 2003.
- Z. Ma, J. Zhang, E. Ji, G. Cao, G. Li, and L. Chu, “Rho kinase inhibition by fasudil exerts antioxidant effects in hypercholesterolemic rats,” Clinical and Experimental Pharmacology and Physiology, vol. 38, no. 10, pp. 688–694, 2011.